Nanobiotix (NBTX) Total Non-Current Liabilities (2018 - 2025)
Nanobiotix (NBTX) posted Total Non-Current Liabilities of $110.3 million for Q4 2025, up 39.1% on a QoQ basis from $79.3 million in Q4 2024, and up 39.1% year-over-year from $79.3 million in Q4 2024.
Nanobiotix (NBTX) has 8 years of Total Non-Current Liabilities data on file, last reported at $110.3 million in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 39.1% year-over-year to $110.3 million; the TTM figure through Dec 2025 stood at $110.3 million (up 39.1% YoY), while the FY2025 annual figure was $107.0 million, up 33.3% from the prior year.
- Total Non-Current Liabilities improved to $110.3 million in Q4 2025, from $79.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $110.3 million in Q4 2025 and bottomed at $43.6 million in Q4 2021.
- A 5-year average of $66.5 million and a median of $49.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities decreased 17.82% — and 2024, when it soared 60.64%.
- Year by year, Total Non-Current Liabilities stood at $43.6 million in 2021, then grew by 14.31% to $49.9 million in 2022, then retreated by 1.04% to $49.3 million in 2023, then soared by 60.64% to $79.3 million in 2024, then jumped by 39.1% to $110.3 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $110.3 million (Q4 2025), $79.3 million (Q4 2024), and $49.3 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 746.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110.28 Mn |
| Jun 30, 2025 | 57.83 Mn |
| Dec 31, 2024 | 79.28 Mn |
| Jun 30, 2024 | 55.93 Mn |
| Dec 31, 2023 | 49.35 Mn |
| Jun 30, 2023 | 48.28 Mn |
| Dec 31, 2022 | 49.87 Mn |
| Jun 30, 2022 | 38.68 Mn |
| Dec 31, 2021 | 43.62 Mn |
| Jun 30, 2021 | 53.52 Mn |
| Dec 31, 2020 | 53.08 Mn |
| Dec 31, 2019 | 48.44 Mn |
| Dec 31, 2018 | 23.24 Mn |